XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of ($0.26) million during the quarter.
XTL Biopharmaceuticals Trading Up 15.7%
Shares of XTL Biopharmaceuticals stock traded up $0.37 during trading on Tuesday, reaching $2.73. The company’s stock had a trading volume of 1,148,763 shares, compared to its average volume of 1,058,812. The company has a 50-day moving average price of $2.56 and a two-hundred day moving average price of $3.58. XTL Biopharmaceuticals has a fifty-two week low of $2.01 and a fifty-two week high of $10.28. The firm has a market cap of $6.02 million, a PE ratio of -4.27 and a beta of 1.49.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research report on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Recommended Stories
- Five stocks we like better than XTL Biopharmaceuticals
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
